MMP23B and melanoma: Ongoing efforts to identify biomarkers to predict the response to anti-CTLA-4 therapy are under way just as additional studies to identify those patients most likely to benefit from MMP-23 inhibition are needed in parallel to those of the role of MMP-23 in melanoma.